USD 1.46
(-2.61%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 7.56 Million USD | -37.06% |
2022 | 12.02 Million USD | 6.13% |
2021 | 11.32 Million USD | 1417.36% |
2020 | 746.5 Thousand USD | -56.96% |
2019 | 1.73 Million USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 8.71 Million USD | 15.19% |
2024 Q2 | 12.01 Million USD | 37.9% |
2023 Q2 | 10.26 Million USD | 13.17% |
2023 FY | 7.56 Million USD | -37.06% |
2023 Q4 | 7.56 Million USD | 8.08% |
2023 Q3 | 7 Million USD | -31.82% |
2023 Q1 | 9.07 Million USD | -24.52% |
2022 Q4 | 12.02 Million USD | -18.67% |
2022 Q3 | 14.78 Million USD | 51.47% |
2022 FY | 12.02 Million USD | 6.13% |
2022 Q2 | 9.75 Million USD | -14.72% |
2022 Q1 | 11.44 Million USD | 1.04% |
2021 Q1 | - USD | -100.0% |
2021 FY | 11.32 Million USD | 1417.36% |
2021 Q4 | 11.32 Million USD | -4.63% |
2021 Q3 | 11.87 Million USD | 0.0% |
2020 FY | 746.5 Thousand USD | -56.96% |
2020 Q4 | 746.5 Thousand USD | 0.0% |
2019 FY | 1.73 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AIM ImmunoTech Inc. | 19.38 Million USD | 60.957% |
Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -31.919% |
Armata Pharmaceuticals, Inc. | 109.96 Million USD | 93.119% |
Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 90.709% |
Azitra, Inc. | 5.11 Million USD | -47.92% |
Can-Fite BioPharma Ltd. | 9.98 Million USD | 24.248% |
Chromocell Therapeutics Corporation | 96.39 Thousand USD | -7750.164% |
Calidi Biotherapeutics, Inc. | 10.01 Million USD | 24.475% |
CEL-SCI Corporation | 30.52 Million USD | 75.214% |
iBio, Inc. | 28.73 Million USD | 73.666% |
Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 92.509% |
Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 88.461% |
Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -73.091% |
NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | 16.24% |
NanoViricides, Inc. | 12.82 Million USD | 40.989% |
Oragenics, Inc. | 4.96 Million USD | -52.363% |
BiomX Inc. | 58.15 Million USD | 86.989% |
BiomX Inc. | 58.15 Million USD | 86.989% |
Protalix BioTherapeutics, Inc. | 84.43 Million USD | 91.038% |
Palatin Technologies, Inc. | 10.74 Million USD | 29.56% |
Scorpius Holdings, Inc. | 51.03 Million USD | 85.174% |
Theriva Biologics, Inc. | 60.21 Million USD | 87.433% |